| License: Creative Commons Attribution 4.0 PDF - Published Version (4MB) |
- URN to cite this document:
- urn:nbn:de:bvb:355-epub-593031
- DOI to cite this document:
- 10.5283/epub.59303
Abstract
The determination of ligand–receptor binding affinities plays a key role in the development process of pharmaceuticals. While the classical radiochemical binding assay uses radioligands, fluorescence-based binding assays require fluorescent probes. Usually, radio- and fluorescence-labeled ligands are dissimilar in terms of structure and bioactivity, and can be used in either radiochemical or ...

Owner only: item control page

Download Statistics